Premium
Rituximab, interferon‐alfa‐2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH ‐ PRO ‐05 study
Author(s) -
CannataOrtiz Jimena,
Nicolás Concepción,
GarcíaNoblejas Ana,
Requena María José,
LópezJiménez Javier,
Alaez Uson Concepción,
Arranz Reyes
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15760
Subject(s) - medicine , rituximab , vincristine , prednisone , follicular lymphoma , bendamustine , cyclophosphamide , oncology , surgery , international prognostic index , progression free survival , gastroenterology , lymphoma , chemotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom